Lab
Medarbor LLC
Medarbor LLC was paid $15.84M by Medicaid between Jan 2018 and Dec 2024, across 109 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.
33Billing provider infoMEDARBOR LLC
BRISTOL, PA 19007
BRISTOL, PA 19007
33aNPI1477076941assigned 07/17/2017
33bProvider typeClinical Medical Laboratory
28Total paid$15.84M
24GClaims724,409
24DCodes billed109
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Pennsylvania
Rank by total paid#11 of 95
Median peer was paid$153K
This provider vs. median104×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 63,068 | $592K | |
| 2019 | 78,070 | $1.39M | |
| 2020 | 151,765 | $4.88M | |
| 2021 | 203,098 | $5.08M | |
| 2022 | 160,212 | $2.91M | |
| 2023 | 56,831 | $806K | |
| 2024incomplete | 11,365 | $170K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 56% | 182,908 | 61,251 | $8.82M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 8.3% | 99,338 | 31,792 | $1.31M |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 7.8% | 32,846 | 23,897 | $1.24M |
| 87150 | 5.0% | 10,203 | 8,021 | $785K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 3.4% | 68,135 | 19,298 | $543K |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.3% | 12,951 | 9,789 | $371K |
| 87481 | 2.3% | 25,195 | 20,060 | $365K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.5% | 1,934 | 1,634 | $239K |
| 87640 | 1.2% | 29,842 | 23,722 | $191K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 7,554 | 2,940 | $146K |
| 87653 | <1% | 23,572 | 18,932 | $108K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 7,712 | 2,493 | $102K |
97 more codes
| 87641 | <1% | 17,406 | $95K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,873 | $91K |
| 87500 | <1% | 16,910 | $90K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,757 | $89K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 5,755 | $84K |
| 87634 | <1% | 4,061 | $82K | |
| 87799 | <1% | 10,024 | $63K | |
| 87541 | <1% | 8,520 | $53K | |
| 87486 | <1% | 4,635 | $47K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 732 | $47K |
| 87581 | <1% | 4,639 | $46K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,763 | $43K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,625 | $39K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,282 | $34K |
| 80361 | <1% | 4,479 | $27K | |
| 80346 | <1% | 3,838 | $27K | |
| 80362 | <1% | 4,588 | $26K | |
| 80329 | <1% | 4,250 | $26K | |
| 80356 | <1% | 4,199 | $26K | |
| 80354 | <1% | 4,376 | $26K | |
| 80373 | <1% | 4,390 | $25K | |
| 80369 | <1% | 4,250 | $25K | |
| 80367 | <1% | 4,277 | $25K | |
| 80372 | <1% | 4,212 | $25K | |
| 80358 | <1% | 4,410 | $25K | |
| 80365 | <1% | 4,430 | $25K | |
| 80353 | <1% | 4,433 | $25K | |
| 80355 | <1% | 4,294 | $25K | |
| 80368 | <1% | 4,247 | $25K | |
| 80360 | <1% | 4,271 | $25K | |
| 80366 | <1% | 4,283 | $25K | |
| 80359 | <1% | 4,556 | $25K | |
| 87542 | <1% | 2,684 | $18K | |
| 80335 | <1% | 1,557 | $16K | |
| 80332 | <1% | 1,551 | $16K | |
| 87631 | <1% | 519 | $16K | |
| 80324 | <1% | 1,556 | $16K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,587 | $15K |
| 83992 | <1% | 3,309 | $15K | |
| 80349 | <1% | 3,410 | $15K | |
| 80371 | <1% | 2,660 | $15K | |
| 80338 | <1% | 2,284 | $14K | |
| 80342 | <1% | 2,480 | $12K | |
| 80336 | <1% | 2,641 | $11K | |
| 80348 | <1% | 3,018 | $11K | |
| 80333 | <1% | 2,677 | $10K | |
| 80325 | <1% | 2,872 | $9K | |
| 87529 | <1% | 185 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 224 | $5K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 51 | $4K |
| 87511 | <1% | 230 | $3K | |
| 86409 | <1% | 157 | $3K | |
| 87186 | <1% | 1,151 | $3K | |
| 87088 | <1% | 2,183 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,761 | $2K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 92 | $2K |
| 82570 | <1% | 2,232 | $2K | |
| 80377 | <1% | 100 | $2K | |
| 86408 | <1% | 180 | $2K | |
| 81003 | <1% | 3,392 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 130 | $1K |
| 80061 | Lipid panel | <1% | 158 | $539.69 |
| 83970 | <1% | 91 | $494.88 | |
| 82670 | <1% | 117 | $486.09 | |
| 82746 | <1% | 137 | $454.18 | |
| 82607 | <1% | 101 | $408.40 | |
| 83880 | <1% | 17 | $376.80 | |
| 84403 | <1% | 90 | $348.16 | |
| 80053 | Comprehensive metabolic panel | <1% | 206 | $320.16 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 90 | $302.94 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 255 | $298.85 |
| 84480 | <1% | 148 | $268.53 | |
| 83090 | <1% | 71 | $219.22 | |
| 82728 | <1% | 116 | $213.90 | |
| 87506 | <1% | 63 | $210.31 | |
| 84145 | <1% | 67 | $202.45 | |
| 84144 | <1% | 81 | $200.00 | |
| 83735 | <1% | 95 | $149.94 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57 | $146.61 |
| 85027 | <1% | 150 | $144.36 | |
| 84436 | <1% | 146 | $130.01 | |
| 82533 | <1% | 67 | $121.21 | |
| 83002 | <1% | 53 | $106.33 | |
| 84466 | <1% | 148 | $96.92 | |
| 82977 | <1% | 70 | $84.88 | |
| 84153 | <1% | 16 | $81.83 | |
| 80076 | <1% | 71 | $68.98 | |
| 83001 | <1% | 52 | $68.63 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 66 | $67.21 |
| 84481 | <1% | 151 | $60.96 | |
| 84479 | <1% | 92 | $58.78 | |
| 83550 | <1% | 114 | $54.55 | |
| 84550 | <1% | 70 | $53.20 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 90 | $40.06 |
| 84439 | <1% | 149 | $39.69 | |
| 83540 | <1% | 91 | $38.40 | |
| 86140 | <1% | 25 | $12.63 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLEGOWSKI, MATTHEW (OPERATION)
| Provider | Location | Paid |
|---|---|---|
| Cleveland Surgical Associates, INC. | North Royalton, OH | $1.03M |
| Encore Clinical Services - PA LLC | Bristol, PA | $12K |
| Encore Wound Care - Kentucky, LLC | Lexington, KY | $716.40 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.